Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Digital therapy plus denosumab for fracture risk prevention and treatment in postmenopausal osteoporosis
ChiCTR2400082832Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab in osteoporosis (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoints: Bone mineral density and Roentgenogram. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2400082832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082832.